Prof Robert presents the results of the phase III COMBI-V trial at a press conference at ECC 2015, the results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma.

COMBI-V compared a combination of two targeted therapies -dabrafenib and trametinib - versus vemurafenib in the first-line treatment of advanced melanoma.

Results of the study have shown that patients given the combined therapy lived significantly longer than did the patients treated with vemurafenib used alone.

Their study has shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

Read the news story for more or watch the interview for more.